Scientists may have found a way to strengthen bones for life

osteoporosis stages hip bone strength.webp

There is a high demand for safe and long -term medications to treat bone loss, which is medically known as osteoporosis. In Germany, about six million people – most of whom are women – are affected by this extensive condition. Therefore, the discovery of new targets to develop medicines is a basic step towards better treatments with lower side effects. GPR133, GPR133, belongs to a receptor group that is still relatively uncomplicated. In a recent study, scientists at the University of Leipzig showed that GPR133 plays a major role in building and maintaining healthy bones.

“If this future is weak due to genetic changes, mice show signs of bone density loss at an early age – similar to osteoporosis in humans. Using AP503, which was recently identified only through a computer screen, explains the professor from the professor, and includes a professor paid from the professor, and includes the professor paid from the professor, and includes the professor Paid Professor.

In bone tissues, GPR133 is activated by the interaction of adjacent bone cells and mechanical strains. This leads to a signal stimulating cells that make up bone (bone bone cells) and prevent extended bone (bone) cells. The result: stronger and more flexible. The new active material AP503 can mimic this natural activation. In the future, it can be used to increase healthy bones and rebuild weak bones – for example, in cases of osteoporosis in women who are going through menopause.

A high possibility for the aging of the population

In a previous study, researchers at the University of Leipzig have already found that activation with AP503 also enhances structural muscles. “The parallel that was recently distributed again sheds back the great potential that this future carries for medical applications in the aging of the population,” says Dr. Julian Lehman, the main author of The Study and urges at the Rudolf Schunheimer Institute for Biochemistry. The Leipzig research team is already working on many follow -up projects to explore the use of AP503 in various diseases and more investigation into the role of GPR133 in the body.

background

Over the course of more than ten years, the study of protein G -associated with adhesion was a major axis at Leipzig University at the Cooperative Research Center 1423, structural dynamics to activate GPCR and its signals. Internationally, Leipzig is a pioneering center in this field of research.

(Tagstotranslate) Women & AMP;#039; Pharmacy Aging Healthy Personal Medicine; Alternative medicine today & amp;#039; health care ; menopause; Diseases and conditions

Post Comment